Timothy J Bensman
Overview
Explore the profile of Timothy J Bensman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith H, Bensman T, Mishra S, Li X, Dixon C, Sheikh J, et al.
J Infect Dis
. 2024 Mar;
230(2):505-513.
PMID: 38502709
On 22 March 2023, the FDA approved rezafungin (Rezzayo) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Rezafungin is an echinocandin...
2.
Jjingo C, Bala S, Waack U, Needles M, Bensman T, McMaster O, et al.
Clin Infect Dis
. 2023 Oct;
78(6):1564-1570.
PMID: 37802928
Allergic bronchopulmonary aspergillosis and invasive fungal diseases represent distinct infectious entities that cause significant morbidity and mortality. Currently, administered inhaled antifungal therapies are unapproved, have suboptimal efficacy, and are associated...
3.
Kitabi E, Bensman T, Earp J, Chilukuri D, Smith H, Ball L, et al.
Clin Infect Dis
. 2022 Jan;
75(2):359.
PMID: 35023546
No abstract available.
4.
Dughbaj M, Jayne J, Park A, Bensman T, Algorri M, Ouellette A, et al.
Antibiotics (Basel)
. 2021 Sep;
10(9).
PMID: 34572625
Vicious cycles of chronic airway obstruction, lung infections with , and neutrophil-dominated inflammation contribute to morbidity and mortality in cystic fibrosis (CF) patients. Rhesus theta defensin-1 (RTD-1) is an antimicrobial...
5.
Kitabi E, Bensman T, Earp J, Chilukuri D, Smith H, Ball L, et al.
Clin Infect Dis
. 2021 Feb;
73(5):903-906.
PMID: 33605994
For treatment of severe malaria, the World Health Organization recommends 3 mg/kg intravenous artesunate in pediatric patients weighing less than 20 kg. Here we describe the Food and Drug Administration's...
6.
Nguyen K, Bensman T, Wei X, Moore J
Antimicrob Agents Chemother
. 2020 Jul;
64(9).
PMID: 32601159
Effective bacterial infection eradication requires not only potent antibacterial agents but also proper dosing strategies. Current practices generally utilize point estimates of the effects of therapeutic agents, even though the...
7.
Jayne J, Bensman T, Schaal J, Park A, Kimura E, Tran D, et al.
Am J Respir Cell Mol Biol
. 2017 Sep;
58(3):310-319.
PMID: 28954201
Acute lung injury (ALI) is a clinical syndrome characterized by acute respiratory failure and is associated with substantial morbidity and mortality. Rhesus θ-defensin (RTD)-1 is an antimicrobial peptide with immunomodulatory...
8.
Bensman T, Wang J, Jayne J, Fukushima L, Rao A, DArgenio D, et al.
Antimicrob Agents Chemother
. 2017 Aug;
61(10).
PMID: 28784670
Acute pulmonary exacerbations (APE) involving are associated with increased morbidity and mortality in cystic fibrosis (CF) patients. Drug resistance is a significant challenge to treatment. Ceftazidime-avibactam (CZA) demonstrates excellent activity...
9.
Bensman T, Jayne J, Sun M, Kimura E, Meinert J, Wang J, et al.
Antimicrob Agents Chemother
. 2017 Jun;
61(8).
PMID: 28559270
Chronic airway infection and inflammation contribute to the progressive loss of lung function and shortened survival of patients with cystic fibrosis (CF). Rhesus theta defensin-1 (RTD-1) is a macrocyclic host...
10.
Beringer P, Bensman T, Ho H, Agnello M, Denovel N, Nguyen A, et al.
J Antimicrob Chemother
. 2015 Oct;
71(1):181-8.
PMID: 26433781
Objectives: Chronic endobronchial infections with Pseudomonas aeruginosa contribute to bronchiectasis and progressive loss of lung function in patients with cystic fibrosis. This study aimed to evaluate the therapeutic potential of...